Overview
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Description
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.
Eligibility
Inclusion Criteria:
- AML with MECOM or atypical 3q26 rearrangements.
- Age ≥18.
- Signed written informed consent according to ICH/EU/GCP and national local laws.
Exclusion Criteria:
- None